Publications
Detailed Information
Safety and efficacy of clonazepam in patients with hemifacial spasm: A double-blind, randomized, placebo-controlled trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baek, Seol-Hee | - |
dc.contributor.author | Shin, Je-Young | - |
dc.contributor.author | Sohn, Sung-Yeon | - |
dc.contributor.author | Park, Kee Hong | - |
dc.contributor.author | Kim, Jun-Soon | - |
dc.contributor.author | Kim, Bongjae | - |
dc.contributor.author | Ahn, So Hyun | - |
dc.contributor.author | Choi, Kyomin | - |
dc.contributor.author | Hong, Yoon-Ho | - |
dc.contributor.author | Sung, Jung-Joon | - |
dc.date.accessioned | 2022-10-07T00:41:01Z | - |
dc.date.available | 2022-10-07T00:41:01Z | - |
dc.date.created | 2022-09-29 | - |
dc.date.issued | 2022-10 | - |
dc.identifier.citation | Parkinsonism and Related Disorders, Vol.103, pp.1-6 | - |
dc.identifier.issn | 1353-8020 | - |
dc.identifier.uri | https://hdl.handle.net/10371/185521 | - |
dc.description.abstract | © 2022 Elsevier LtdIntroduction: Hemifacial spasm (HFS) is an involuntary intermittent twitching of the facial muscles. Medical and surgical treatments can be considered for HFS. Among medical treatments, clonazepam is a benzodiazepine used to treat epilepsy, psychiatric symptoms, and movement disorders. This study aimed to investigate the efficacy and safety of clonazepam for the treatment of HFS. Methods: This randomized double-blind placebo-controlled trial prospectively enrolled patients with HFS aged 20–79 years. The patients were randomly assigned in a 1:1 ratio to receive either clonazepam (0.5 mg twice daily) or a placebo for 4 weeks. All participants underwent clinical assessment and laboratory tests at baseline and visit 2. The primary endpoint was the clinical global impression-improvement (CGI-I) score at visit 2. Results: A total of 34 patients with HFS assessed for eligibility were enrolled between April 2015 and November 2016. Among them, two patients were withdrawn before randomization. Thus, the intention-to-treat analysis included 32 patients with HFS. The median CGI-I scores at visit 2 did not differ significantly between the clonazepam (3; range 1–6) and placebo (3.5; range 3–5) groups. In the safety analysis, only mild or no serious adverse events were observed. Conclusion: The results of this study demonstrated the safety of clonazepam in patients with HFS. However, clonazepam did not show a statistically significant effect on HFS. Further studies are needed to provide evidence of the clinical benefits in patients with HFS. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier BV | - |
dc.title | Safety and efficacy of clonazepam in patients with hemifacial spasm: A double-blind, randomized, placebo-controlled trial | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.parkreldis.2022.07.025 | - |
dc.citation.journaltitle | Parkinsonism and Related Disorders | - |
dc.identifier.scopusid | 2-s2.0-85136036280 | - |
dc.citation.endpage | 6 | - |
dc.citation.startpage | 1 | - |
dc.citation.volume | 103 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Sung, Jung-Joon | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.